Follow
Enrico N. De Toni
Enrico N. De Toni
Professor of Medicine, University of Munich
Verified email at med.uni-muenchen.de - Homepage
Title
Cited by
Cited by
Year
Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
GK Abou-Alfa, G Lau, M Kudo, SL Chan, RK Kelley, J Furuse, ...
NEJM evidence 1 (8), EVIDoa2100070, 2022
7892022
The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
W Tang, Z Chen, W Zhang, Y Cheng, B Zhang, F Wu, Q Wang, S Wang, ...
Signal transduction and targeted therapy 5 (1), 87, 2020
6892020
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma …
GK Abou-Alfa, SL Chan, M Kudo, G Lau, RK Kelley, J Furuse, ...
Journal of Clinical Oncology 40 (4_suppl), 379-379, 2022
3632022
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma
J Ricke, HJ Klümpen, H Amthauer, I Bargellini, P Bartenstein, EN de Toni, ...
Journal of hepatology 71 (6), 1164-1174, 2019
3242019
The role of the novel Th17 cytokine IL-26 in intestinal inflammation
J Dambacher, F Beigel, K Zitzmann, EN De Toni, B Göke, HM Diepolder, ...
Gut 58 (9), 1207-1217, 2009
3172009
The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells
K Zitzmann, EN De Toni, S Brand, B Göke, J Meinecke, G Spöttl, ...
Neuroendocrinology 85 (1), 54-60, 2007
2062007
Checkpoint Inhibitors: the diagnosis and treatment of side effects
L Heinzerling, EN de Toni, G Schett, G Hundorfean, L Zimmer
Deutsches Ärzteblatt International 116 (8), 119, 2019
1552019
EFEMP1 Expression Promotes In vivo Tumor Growth in Human Pancreatic Adenocarcinoma
H Seeliger, P Camaj, I Ischenko, A Kleespies, EN De Toni, SE Thieme, ...
Molecular Cancer Research 7 (2), 189-198, 2009
1242009
Use of checkpoint inhibitors in liver transplant recipients
S Munker, EN De Toni
United European gastroenterology journal 6 (7), 970-973, 2018
1112018
Inhibition of ataxia telangiectasia-and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133+ …
E Gallmeier, PC Hermann, MT Mueller, JG Machado, A Ziesch, ...
Stem Cells 29 (3), 418-429, 2011
1112011
Inhibition of c-Jun-N-terminal-Kinase Sensitizes Tumor Cells to CD95-Induced Apoptosis and Induces G2/M Cell Cycle Arrest
C Kuntzen, N Sonuc, EN De Toni, C Opelz, SR Mucha, AL Gerbes, ...
Cancer research 65 (15), 6780-6788, 2005
1042005
OPG is regulated by β-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer
EN De Toni, SE Thieme, A Herbst, A Behrens, P Stieber, A Jung, H Blum, ...
Clinical cancer research 14 (15), 4713-4718, 2008
1012008
EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells
P Camaj, H Seeliger, I Ischenko, S Krebs, H Blum, EN De Toni, ...
Walter de Gruyter 390 (12), 1293-1302, 2009
982009
Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study
EN De Toni, A Schlesinger-Raab, M Fuchs, W Schepp, U Ehmer, ...
Gut 69 (1), 168-176, 2020
952020
Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient.
EN De Toni, AL Gerbes
Gastroenterology 152 (6), 1631-1633, 2017
932017
Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling
I Ischenko, P Camaj, H Seeliger, A Kleespies, M Guba, EN De Toni, ...
Oncogene 27 (57), 7212-7222, 2008
882008
Mood, cognition and EEG changes during interferon α (alpha-IFN) treatment for chronic hepatitis C
P Amodio, EN De Toni, L Cavalletto, D Mapelli, E Bernardinello, ...
Journal of affective disorders 84 (1), 93-98, 2005
852005
Targeting cyclin dependent kinase 5 in hepatocellular carcinoma–A novel therapeutic approach
SM Ehrlich, J Liebl, MA Ardelt, T Lehr, EN De Toni, D Mayr, L Brandl, ...
Journal of hepatology 63 (1), 102-113, 2015
822015
JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand
SR Mucha, A Rizzani, AL Gerbes, P Camaj, WE Thasler, CJ Bruns, ...
Gut 58 (5), 688-698, 2009
812009
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
L Rimassa, G Abbadessa, N Personeni, C Porta, I Borbath, B Daniele, ...
Oncotarget 7 (45), 72622, 2016
732016
The system can't perform the operation now. Try again later.
Articles 1–20